Here, through a combination of qPCR and epigenetics-related activity assays, we found that Nosustrophine, compared to vehicle-treated transgenic mice, regulated: AD-related PSEN2 and APOE gene expression, inflammation-related (NOS3 and COX-2) gene expression in 3–4-month-old only, global (5mC)- and de novo DNA methylation (DNMT3a), HDAC3 expression and HDAC activity in 3–4-month-old mice, and Aβ1-42 levels, SIRT1 expression and acetylated histone H3 protein levels in 8–9-month-old mice (Figure 12A,B). This evidence concerns the gene DNMT3A and Alzheimer disease.